Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Edwards Lifesciences Corp
Bear Case (25th pct.)
-68.0% vs price
Base Case (Median)
-65.6% vs price
Bull Case (75th pct.)
-59.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $28.02 | -67.1% | High (40%) |
| PE Comparable | $39.07 | -54.1% | Medium (25%) |
| Growth Trajectory DCF | $30.07 | -64.7% | Medium (20%) |
| Graham Number | $26.50 | -68.9% | Medium (40%) |
| EV/EBITDA | $29.33 | -65.6% | Medium (20%) |
| EV/FCF | $53.62 | -37.0% | Medium (20%) |
| Earnings Power Value | $23.78 | -72.1% | Medium (50%) |
Based on 7 out of 7 methods, EW appears overvalued at the current price of $85.15. The base case fair value of $29.33 implies 65.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.